Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results.

G Bacci, M Avella, A Brach Del Prevert, R Capanna, G Fiorentini, C Malaguti, P Picci, P Rosito, M Campanacci
{"title":"Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results.","authors":"G Bacci,&nbsp;M Avella,&nbsp;A Brach Del Prevert,&nbsp;R Capanna,&nbsp;G Fiorentini,&nbsp;C Malaguti,&nbsp;P Picci,&nbsp;P Rosito,&nbsp;M Campanacci","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Forty-nine patients with localized osteosarcoma of the extremities were treated with a new protocol of neoadjuvant chemotherapy. Preoperatively the patients received high-dose methotrexate intravenously, followed after a week by cisplatinum intra-arterially for a continuous infusion over a 72-hour period, plus adriamycin intravenously infused over an 8-hour period. In all cases the clinical and radiographic response was good and in 44 cases (89.7%) it was possible to perform conservative surgery. The histologic examination of the surgical specimen resulted in necrosis being \"good\" (greater than or equal to 90% of necrosis) in 41 patients (83.6%). This percentage of \"good necrosis\" was significantly higher than the percentage previously obtained in our Center as well as in others for preoperative treatment of this tumor. Up to now, patients with localized osteosarcoma of the extremities who showed a good histologic response to the preoperative chemotherapy have had a very good prognosis (82% of patients are continuously disease-free). These results suggest that this new regimen represents a substantial improvement in the treatment of this disease.</p>","PeriodicalId":9733,"journal":{"name":"Chemioterapia : international journal of the Mediterranean Society of Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1988-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemioterapia : international journal of the Mediterranean Society of Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Forty-nine patients with localized osteosarcoma of the extremities were treated with a new protocol of neoadjuvant chemotherapy. Preoperatively the patients received high-dose methotrexate intravenously, followed after a week by cisplatinum intra-arterially for a continuous infusion over a 72-hour period, plus adriamycin intravenously infused over an 8-hour period. In all cases the clinical and radiographic response was good and in 44 cases (89.7%) it was possible to perform conservative surgery. The histologic examination of the surgical specimen resulted in necrosis being "good" (greater than or equal to 90% of necrosis) in 41 patients (83.6%). This percentage of "good necrosis" was significantly higher than the percentage previously obtained in our Center as well as in others for preoperative treatment of this tumor. Up to now, patients with localized osteosarcoma of the extremities who showed a good histologic response to the preoperative chemotherapy have had a very good prognosis (82% of patients are continuously disease-free). These results suggest that this new regimen represents a substantial improvement in the treatment of this disease.

四肢骨肉瘤的新辅助化疗。术前大剂量甲氨蝶呤化疗后顺铂和阿霉素对原发肿瘤有较好的疗效。初步结果。
本文对49例肢体局部骨肉瘤患者进行了新辅助化疗。术前患者接受大剂量甲氨蝶呤静脉滴注,一周后顺铂动脉内连续输注72小时,加阿霉素静脉滴注8小时。在所有病例中,临床和影像学反应良好,44例(89.7%)可以进行保守手术。41例(83.6%)患者手术标本的组织学检查显示坏死“良好”(坏死程度大于或等于90%)。这一“良性坏死”的百分比明显高于我们中心和其他术前治疗该肿瘤的病例。到目前为止,对术前化疗有良好组织学反应的肢体局限性骨肉瘤患者预后都很好(82%的患者持续无病)。这些结果表明,这种新方案代表了这种疾病治疗的实质性改进。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信